Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: CorMedix is a biopharmaceutical company focused on therapeutic products for life-threatening diseases. Its primary product is DefenCath, an antimicrobial catheter lock solution for hemodialysis patients. On August 29, 2025, the Company acquired Melinta Therapeutics, LLC, significantly expanding its portfolio to include six marketed infectious disease products (REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA) and one cardiovascular product (TOPROL-XL).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $311,709 | $43,472 |
| Net Income (Loss) | $163,055 | $(17,930) |
| Operating Income (Loss) | $150,141 | $(22,356) |
| Gross Profit | $275,748 | $40,282 |
| Operating Cash Flow | $175,046 | $(50,615) |
| Cash & Equivalents (Year End) | $144,837 | $40,651 |
| Convertible Senior Notes (Net) | $144,626 | $0 |
Note: 2025 results include Melinta operations only from the August 29, 2025 acquisition date. Results are not directly comparable to 2024 without pro forma adjustments.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 617% to $311.7 million, driven by DefenCath sales growth ($258.8 million) and the inclusion of Melinta portfolio sales ($45.5 million) post-acquisition.
- Profitability Turnaround: The Company achieved a net income of $163.1 million in 2025, reversing a net loss of $17.9 million in 2024. This was primarily due to strong product sales and a $61.5 million release of valuation allowance on deferred tax assets.
- Acquisition Impact: The Melinta acquisition added significant intangible assets ($391.1 million) and goodwill ($30.0 million), resulting in $13.9 million of intangible amortization expense in 2025 compared to $0.2 million in 2024.
- Financing Activities: The Company raised $150.0 million via 4.00% Convertible Senior Notes due 2030 and $82.4 million via a Follow-On common stock offering in 2025 to fund the Melinta acquisition.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- DefenCath Reimbursement: Management anticipates a significant decline in net pricing for DefenCath in Q3 and Q4 2026 due to the transition from TDAPA (Transitional Drug Add-on Payment Adjustment) to a post-TDAPA add-on adjustment. However, they estimate reimbursement levels may improve in 2027.
- REZZAYO Development: The Company expects to announce top-line data for the Phase III ReSPECT clinical trial (prophylaxis of invasive fungal infections) in Q2 2026. Success could trigger milestone payments of up to $25 million to former Melinta equity holders.
- Liquidity: As of December 31, 2025, the Company has $148.5 million in cash, cash equivalents, and short-term investments, sufficient to fund operations for at least 12 months.
Risks and Contingencies
- Customer Concentration: The top three customers accounted for 79% of total revenue in 2025. Loss of a major customer could materially impact results.
- Internal Control Material Weakness: Management identified a material weakness in internal controls over financial reporting related to the review of significant, non-routine transactions (specifically regarding the Melinta acquisition accounting). Remediation efforts are underway.
- Legal Proceedings: The Company is involved in securities class action litigation and derivative litigation regarding alleged misstatements related to DefenCath manufacturing and FDA approval. A settlement was reached in the derivative litigation in January 2026, pending court approval.
- Patent Litigation: Ongoing litigation regarding MINOCIN IV patents against generic manufacturers (Nexus Pharmaceuticals and Gland Pharma) poses a risk to future revenue if patents are invalidated.
Investor Verification Checklist
- Reimbursement Transition: Verify the specific impact of the July 2026 TDAPA-to-post-TDAPA transition on DefenCath net pricing and volume assumptions.
- Internal Controls: Monitor the progress of remediation for the identified material weakness in internal controls over financial reporting.
- REZZAYO Trial Data: Track the Q2 2026 announcement of the ReSPECT Phase III trial results, which is critical for potential milestone payments and market expansion.
- Customer Concentration: Assess the stability of contracts with the top three customers representing 79% of revenue.
- Legal Settlements: Confirm the final approval and terms of the derivative litigation settlement and the status of the securities class action.